| Name | Title | Contact Details |
|---|---|---|
Suresha Venkataraya |
Chief Executive Officer | Profile |
Inogen`s mission to improve the quality of life of supplemental oxygen users began in 2001 when Mae, a beloved Grandmother, was prescribed oxygen therapy. Learn more about Mae`s Story here: http://www.inogen.com/about-inogen/meet-mae/. Inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. We estimate that more than 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy. Our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. We believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. With each step we take to improve our products and service, our customers take another step toward more freedom.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
DOTMED.COM Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Telemedicine Solutions, LLC is a Wilmette, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
HepaHope is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.